Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to…
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illuminas Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a…
International Cancer Organizations Present Collaborative Work During Oncology Event in China
The National Comprehensive Cancer Network (NCCN) is honored to participate in the…
International Cancer Organizations Present Collaborative Work During Oncology Event in China
The National Comprehensive Cancer Network (NCCN) is honored to participate in the…
International Cancer Organizations Present Collaborative Work During Oncology Event in China
The National Comprehensive Cancer Network (NCCN) is honored to participate in the…
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov.…
International Cancer Organizations Present Collaborative Work During Oncology Event in China
The National Comprehensive Cancer Network (NCCN) is honored to participate in the…
International Cancer Organizations Present Collaborative Work During Oncology Event in China
The National Comprehensive Cancer Network (NCCN) is honored to participate in the…
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology…